BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 29110262)

  • 21. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
    Peters S; Kerr KM; Stahel R
    Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitors: new strategies to checkmate cancer.
    Wilson RAM; Evans TRJ; Fraser AR; Nibbs RJB
    Clin Exp Immunol; 2018 Feb; 191(2):133-148. PubMed ID: 29139554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.
    Smith MH; Bass AR
    Arthritis Care Res (Hoboken); 2019 Mar; 71(3):362-366. PubMed ID: 29125905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet-related indices in patients with lung cancer with nivolumab.
    Nomura S; Yokoi T; Kurata T
    Platelets; 2018 Mar; 29(2):207-208. PubMed ID: 29119852
    [No Abstract]   [Full Text] [Related]  

  • 26. Synergistic anticancer activity of a novel oral chemotherapeutic agent containing trifluridine and tipiracil in combination with anti-PD-1 blockade in microsatellite stable-type murine colorectal cancer cells.
    Suzuki N; Tsukihara H; Nakagawa F; Kobunai T; Takechi T
    Am J Cancer Res; 2017; 7(10):2032-2040. PubMed ID: 29119052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma.
    Heymann MF; Lézot F; Heymann D
    Cell Immunol; 2019 Sep; 343():103711. PubMed ID: 29117898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis.
    Abdel-Rahman O
    Clin Respir J; 2018 May; 12(5):1809-1819. PubMed ID: 29115057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infiltration of metastatic lymph nodes with PD-1
    Wang S; Song Y; Morse MA; Sun P; Qiao G; Wang X; Zhou X; Hobeika A; Ren J; Lyerly HK
    Am J Cancer Res; 2020; 10(12):4435-4449. PubMed ID: 33415009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumor heterogeneity: A new perspective on colorectal cancer research.
    Zheng Z; Yu T; Zhao X; Gao X; Zhao Y; Liu G
    Cancer Med; 2020 Oct; 9(20):7637-7645. PubMed ID: 32853464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones.
    Riquet M; Arame A; Foucault C; Le Pimpec Barthes F
    Interact Cardiovasc Thorac Surg; 2010 Sep; 11(3):260-4. PubMed ID: 20573650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Routine high-throughput targeted sequencing of lymphoproliferative diseases : Clinical utility and challenges].
    Menter T; Dirnhofer S; Tzankov A
    Pathologe; 2020 Dec; 41(Suppl 2):143-148. PubMed ID: 33270163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.
    Legras A; Roussel H; Mangiameli G; Arame A; Grand B; Pricopi C; Badia A; Gibault L; Badoual C; Fabre E; Laurent-Puig P; Blons H; Le Pimpec-Barthes F
    Pathol Oncol Res; 2019 Jan; 25(1):319-325. PubMed ID: 29110262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
    Yip PY; Yu B; Cooper WA; Selinger CI; Ng CC; Kennedy CW; Kohonen-Corish MR; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole SA
    J Thorac Oncol; 2013 Apr; 8(4):408-14. PubMed ID: 23392229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Border between N1 and N2 stations in lung carcinoma: lessons from lymph node metastatic patterns of lower lobe tumors.
    Okada M; Sakamoto T; Yuki T; Mimura T; Nitanda H; Miyoshi K; Tsubota N
    J Thorac Cardiovasc Surg; 2005 Apr; 129(4):825-30. PubMed ID: 15821650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.